服用甲氧苄啶/磺胺甲恶唑期间出现的间质性肺疾病。
Interstitial lung disease during trimethoprim/sulfamethoxazole administration.
作者信息
Yuzurio Syota, Horita Naokatsu, Shiota Yutaro, Kanehiro Arihiko, Tanimoto Mitsune
机构信息
Department of Respiratory Medicine, Kure-Kyosai Hospital, Kure, Hiroshima 737-8505, Japan.
出版信息
Acta Med Okayama. 2010 Jun;64(3):181-7. doi: 10.18926/AMO/40010.
We studied clinical and radiographic features of interstitial lung disease (ILD) during trimethoprim/sulfamethoxazole (TMP/SMX) administration. Ten patients who had received prednisolone treatment for underlying diffuse pulmonary disease showed various ILDs after introduction of TMP/SMX. The radiographic features of the ILDs were not consistent with infectious disease or exacerbation of the underlying disease, and these diagnoses were excluded radiographically and on clinical grounds during the differential diagnosis of the ILDs. These ILDs emerged relatively early after introduction of TMP/SMX, which is consistent with the former case report of drug-induced ILD (DI-ILD) caused by TMP/SMX. Therefore DI-ILDs caused by TMP/SMX were suspected in these cases. In most of these cases, the ILDs were clinically mild and disappeared immediately although administration of TMP/SMX was continued.
我们研究了在服用甲氧苄啶/磺胺甲恶唑(TMP/SMX)期间间质性肺疾病(ILD)的临床和影像学特征。10例因潜在的弥漫性肺部疾病接受泼尼松龙治疗的患者在开始使用TMP/SMX后出现了各种ILD。这些ILD的影像学特征与传染病或潜在疾病的加重不一致,并且在对ILD进行鉴别诊断时,通过影像学和临床依据排除了这些诊断。这些ILD在引入TMP/SMX后相对较早出现,这与之前关于TMP/SMX引起的药物性ILD(DI-ILD)的病例报告一致。因此,在这些病例中怀疑是由TMP/SMX引起的DI-ILD。在大多数这些病例中,ILD在临床上较轻,尽管继续服用TMP/SMX,但症状立即消失。